På svenska
Celebrating
20 years

Bringing HOPE through science

This is Oncopeptides

Oncopeptides is a global biotech company focused on the development of targeted
therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. 

Bringing HOPE through science
Celebrating
20 years

This is Oncopeptides

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Oncopeptides brings hope to patients through passionate people, innovative science, and transformative medicines.
2020 in brief

2020 – A year of TRANS­FORmATION

Q1

January 1–March 31

  • Top line results from pivotal phase 2 HORIZON study presented, including 26% Overall Response Rate of melflufen in triple-class refractory multiple myeloma patients

  • The Lancet Hematology published detailed results from international multicenter study, O-12-M1

  • We announced that Covid-19 would not significantly affect ongoing pivotal studies, temporary pause to recruitment for new and explorative studies

Q2

April 1–June 30

  • NDA for accelerated approval of melflufen submitted to FDA

  • A preclinical drug development laboratory was established to strengthen PDC technology platform and build future pipelines

  • Directed share issue of SEK 1,414M (USD 144M) to leading life science investors

Q3

July 1–September 30

  • Marty J Duvall appointed CEO, effective July 1; Jakob Lindberg became Chief Scientific Officer

  • FDA granted priority review of melflufen in patients with triple-class refractory multiple myeloma. Target review date (PDUFA) was set for February 28, 2021

  • Patient enrolment in phase 3 OCEAN study completed; 495 patients enrolled

Q4

October 1–December 31

  • First patient enrolled in phase 3 LIGHTHOUSE combination study in multiple myeloma

  • New phase 2 ANCHOR data, 11 abstracts, including an oral presentation presented at the annual ASH meeting

  • Announcement that a conditional marketing authorization application of melflufen in EU will be submitted in Q2 2021

Watch Marty J Duvall’s statement (2 min 39 sec)
Letter from the CEO

Bringing hope through science

This past year has been a transformational one for Oncopeptides highlighted by the FDA acceptance and priority review of our NDA submission for melflufen which resulted in accelerated approval and US launch in the beginning of 2021. Not many emerging biotech companies cross the finish line in terms of launching a product that can make a significant difference for patients.

CEO, Marty J Duvall

Watch Marty J Duvall’s statement (2 min 39 sec)
Equity story

An emerging global biotech company

Focused commercial and regulatory strategy with the first product on the market

Commercialization phase

  • Commericalization in the US with a dedicated sales and medical affairs organisation

  • Planned submission to EMA for a conditional marketing authorization of melflufen

  • Partnering strategy for Japan

Rapidly growing market

  • The number of patients diagnosed with myeloma is increasing

  • Improved treatment outcomes grow number of patients in later lines of therapy

  • Resistance to therapy is increasing

Broad clinical program supporting future growth and value creation

Comprehensive clinical program

  • Clinical program designed to support potential use in a broader patient population and in earlier lines of therapy​​​​

  • The first confirmatory phase 3 study OCEAN designed to meet primary endpoint with a superiority or a non-inferiority result

  • The LIGHTHOUSE phase 3 combination study may enable melflufen to be used in combination treatments

Melflufen – a unique mechanism of action

  • First anti-cancer peptide drug conjugate leveraging aminopeptidases

  • Comprehensive clinical program designed to broaden label

Proprietary PDC platform lays foundation for future growth

Peptide Drug Conjugate Platform (PDC)

  • PDC delivers fast and selective cytotoxic activity to cancer cells while protecting healthy cells

  • Potential to develop targeted treatments for several forms of cancers e.g AML and DLBCL

  • Second drug candidate OPD5, entering clinical development in stemcell transplantation in multiple myeloma

  • PDC platform validated through melflufen

Investment profile

  • Significant milestones to be delivered over the coming years

  • Growing number of shareholders. 17,000 shareholders continues to provide high
    liquidity in the stock

Broad clinical program supporting future growth and value creation for all our stakeholders
Sustainability

We are on a journey

Oncopeptides is on a journey. We know where we need to be in terms of sustainability and corporate responsibility and we are taking substantive steps to get there. We are an open and transparent company and are currently preparing to measure key indicators that demonstrate how we actively reduce our environmental impact and conduct business responsibly.

Environmental
responsibilities

Oncopeptides operates in a highly regulated space, where environmental impacts are tightly controlled. However, we continue to improve our understanding of our environmental footprint and thereby reduce it further. In 2020, we took steps towards establishing key performance indicators and making the reduction of environmental impacts an integral component of our decision-making processes.

Social
responsibility

Social responsibility: Why social issues matter to Oncopeptides. Oncopeptides takes its role and responsibilities in society very seriously. We strive to have positive impacts wherever we are present – in the local communities where we conduct sales, research, and manufacturing, with our employees, suppliers, and all other stakeholders.

Responsible
Governance

We believe that we should operate responsibly through business ethics and a policy framework to build a sustainable organization. This benefits society and creates value for our shareholders and other stakeholders. Furthermore, good governance helps us attract and retain talent, manage costs, and build trust with employees, customers, patients, suppliers, and stakeholders.

Heading

Heading

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.